🇺🇸 FDA
Pipeline program

OPC-108459

269-13-001

Phase 1 small_molecule completed

Quick answer

OPC-108459 for Atrial Fibrillation is a Phase 1 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Beijing Research Institute
Indication
Atrial Fibrillation
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials